Multidisciplinary Intervention in Radiation-Associated Angiosarcoma of the Breast: Patterns of Recurrence and Response to Treatment.
Journal
Annals of surgical oncology
ISSN: 1534-4681
Titre abrégé: Ann Surg Oncol
Pays: United States
ID NLM: 9420840
Informations de publication
Date de publication:
Jan 2022
Jan 2022
Historique:
received:
11
01
2021
accepted:
01
07
2021
pubmed:
20
8
2021
medline:
22
12
2021
entrez:
19
8
2021
Statut:
ppublish
Résumé
Radiation-associated angiosarcoma (RAAS) of the breast is an aggressive malignancy affecting 1 in 1000 breast cancer patients. This study aimed to determine differences in treatments and outcomes for RAAS initially managed through a sarcoma multi-disciplinary team (SMDT) compared with an outside center (OC) and to describe outcomes after recurrence. Patients with a diagnosis of breast RAAS between 2004 and 2019 were identified from our sarcoma database. Clinicopathologic characteristics, recurrence patterns, and factors predictive of survival were assessed. Differences in local recurrence-free survival (LRFS) and disease-specific survival (DSS) were estimated using Kaplan-Meier and compared using the log-rank test. Surgery was performed for 49 women with RAAS, who had a median age of 74 years (range 41-89 years). Primary management was performed by SMDT for 26 patients and by OC for 23 patients. Radical mastectomy and reconstruction were performed for 96% of the SMDT group versus 17% of the OC group (p = 0.00001). The proportion patients who received chemotherapy, radiation, or both was 42.3% in the SMDT group and 0% in the OC group. During a median follow-up period of 26 months, recurrence was experienced by 38% (10/26) of the SMDT cohort and 83% (19/23) of the OC cohort (p = 0.002). The 3-year LRFS was better in the SMDT cohort (59.3% vs 31.8%; p = 0.019). Of the 29 recurrences 16 received chemotherapy and 6 received radiation, surgery, or both. At the last follow-up visit, 20 patients were in first remission, 1 patient was in second remission, 8 patients were alive with disease, and 20 patients had died of disease. Initial treatment by SMDT was associated with more extensive surgery, multimodal treatments, and a better 3-year LRFS. Patients with breast RAAS likely benefit from early referral and treatment by an SMDT.
Sections du résumé
BACKGROUND
BACKGROUND
Radiation-associated angiosarcoma (RAAS) of the breast is an aggressive malignancy affecting 1 in 1000 breast cancer patients. This study aimed to determine differences in treatments and outcomes for RAAS initially managed through a sarcoma multi-disciplinary team (SMDT) compared with an outside center (OC) and to describe outcomes after recurrence.
METHODS
METHODS
Patients with a diagnosis of breast RAAS between 2004 and 2019 were identified from our sarcoma database. Clinicopathologic characteristics, recurrence patterns, and factors predictive of survival were assessed. Differences in local recurrence-free survival (LRFS) and disease-specific survival (DSS) were estimated using Kaplan-Meier and compared using the log-rank test.
RESULTS
RESULTS
Surgery was performed for 49 women with RAAS, who had a median age of 74 years (range 41-89 years). Primary management was performed by SMDT for 26 patients and by OC for 23 patients. Radical mastectomy and reconstruction were performed for 96% of the SMDT group versus 17% of the OC group (p = 0.00001). The proportion patients who received chemotherapy, radiation, or both was 42.3% in the SMDT group and 0% in the OC group. During a median follow-up period of 26 months, recurrence was experienced by 38% (10/26) of the SMDT cohort and 83% (19/23) of the OC cohort (p = 0.002). The 3-year LRFS was better in the SMDT cohort (59.3% vs 31.8%; p = 0.019). Of the 29 recurrences 16 received chemotherapy and 6 received radiation, surgery, or both. At the last follow-up visit, 20 patients were in first remission, 1 patient was in second remission, 8 patients were alive with disease, and 20 patients had died of disease.
CONCLUSION
CONCLUSIONS
Initial treatment by SMDT was associated with more extensive surgery, multimodal treatments, and a better 3-year LRFS. Patients with breast RAAS likely benefit from early referral and treatment by an SMDT.
Identifiants
pubmed: 34409543
doi: 10.1245/s10434-021-10477-1
pii: 10.1245/s10434-021-10477-1
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
522-532Informations de copyright
© 2021. Society of Surgical Oncology.
Références
Cahan WG, Woodard HQ, et al. Sarcoma arising in irradiated bone: report of 11 cases. Cancer. 1948;1:3–29.
doi: 10.1002/1097-0142(194805)1:1<3::AID-CNCR2820010103>3.0.CO;2-7
Gladdy RA, Qin LX, Moraco N, et al. Do radiation-associated soft tissue sarcomas have the same prognosis as sporadic soft tissue sarcomas? J Clin Oncol. 2010;28:2064–9.
doi: 10.1200/JCO.2009.25.1728
Young RJ, Brown NJ, Reed MW, Hughes D, Woll PJ. Angiosarcoma. Lancet Oncol. 2010;11:983–91.
doi: 10.1016/S1470-2045(10)70023-1
Erel E, Vlachou E, Athanasiadou M, Hassan S, Chandrasekar CR, Peart F. Management of radiation-induced sarcomas in a tertiary referral centre: a review of 25 cases. Breast. 2010;19:424–7.
doi: 10.1016/j.breast.2010.04.006
Quadros CA, Vasconcelos A, Andrade R, et al. Good outcome after neoadjuvant chemotherapy and extended surgical resection for a large radiation-induced high-grade breast sarcoma. Int Semin Surg Oncol. 2006;3:18.
doi: 10.1186/1477-7800-3-18
D’Angelo SP, Antonescu CR, Kuk D, et al. High-risk features in radiation-associated breast angiosarcomas. Br J Cancer. 2013;109:2340–6.
doi: 10.1038/bjc.2013.590
Torres KE, Ravi V, Kin K, et al. Long-term outcomes in patients with radiation-associated angiosarcomas of the breast following surgery and radiotherapy for breast cancer. Ann Surg Oncol. 2013;20:1267–74.
doi: 10.1245/s10434-012-2755-y
Morgan EA, Kozono DE, Wang Q, et al. Cutaneous radiation-associated angiosarcoma of the breast: poor prognosis in a rare secondary malignancy. Ann Surg Oncol. 2012;19:3801–8.
doi: 10.1245/s10434-012-2563-4
Cha C, Antonescu CR, Quan ML, Maru S, Brennan MF. Long-term results with resection of radiation-induced soft tissue sarcomas. Ann Surg. 2004;239:903–9 (discussion 909-10).
doi: 10.1097/01.sla.0000128686.51815.8b
Seinen JM, Styring E, Verstappen V, et al. Radiation-associated angiosarcoma after breast cancer: high recurrence rate and poor survival despite surgical treatment with R0 resection. Ann Surg Oncol. 2012;19:2700–6.
doi: 10.1245/s10434-012-2310-x
Gervais MK, Burtenshaw SM, Maxwell J, et al. Clinical outcomes in breast angiosarcoma patients: a rare tumor with unique challenges. J Surg Oncol. 2017;116:1056–61.
doi: 10.1002/jso.24780
West JG, Qureshi A, West JE, et al. Risk of angiosarcoma following breast conservation: a clinical alert. Breast J. 2005;11:115–23.
doi: 10.1111/j.1075-122X.2005.21548.x
Yap J, Chuba PJ, Thomas R, et al. Sarcoma as a second malignancy after treatment for breast cancer. Int J Radiat Oncol Biol Phys. 2002;52:1231–7.
doi: 10.1016/S0360-3016(01)02799-7
Cohen-Hallaleh RB, Smith HG, Smith RC, et al. Radiation-induced angiosarcoma of the breast: outcomes from a retrospective case series. Clin Sarcoma Res. 2017;7:15.
doi: 10.1186/s13569-017-0081-7
Bryant AK, Banegas MP, Martinez ME, Mell LK, Murphy JD. Trends in radiation therapy among cancer survivors in the United States, 2000–2030. Cancer Epidemiol Biomark Prev. 2017;26:963–70.
doi: 10.1158/1055-9965.EPI-16-1023
Bonito FJP, de Almeida Cerejeira D, Dahlstedt-Ferreira C, Oliveira Coelho H, Rosas R. Radiation-induced angiosarcoma of the breast: a review. Breast J. 2020;26:458–63.
doi: 10.1111/tbj.13504
Lucas DR. Angiosarcoma, radiation-associated angiosarcoma, and atypical vascular lesion. Arch Pathol Lab Med. 2009;133:1804–9.
doi: 10.5858/133.11.1804
Fineberg S, Rosen PP. Cutaneous angiosarcoma and atypical vascular lesions of the skin and breast after radiation therapy for breast carcinoma. Am J Clin Pathol. 1994;102:757–63.
doi: 10.1093/ajcp/102.6.757
Fraga-Guedes C, Gobbi H, Mastropasqua MG, Botteri E, Luini A, Viale G. Primary and secondary angiosarcomas of the breast: a single-institution experience. Breast Cancer Res Treat. 2012;132:1081–8.
doi: 10.1007/s10549-011-1931-2
Biswas T, Tang P, Muhs A, Ling M. Angiosarcoma of the breast: a rare clinicopathological entity. Am J Clin Oncol. 2009;32:582–6.
doi: 10.1097/COC.0b013e3181967f09
Sheth GR, Cranmer LD, Smith BD, Grasso-Lebeau L, Lang JE. Radiation-induced sarcoma of the breast: a systematic review. Oncologist. 2012;17:405–18.
doi: 10.1634/theoncologist.2011-0282
Feinberg L, Srinivasan A, Singh JK, et al. Impact of specialist management on survival from radiation-associated angiosarcoma of the breast. Br J Surg. 2018;105:401–9.
doi: 10.1002/bjs.10696
Thijssens KM, van Ginkel RJ, Suurmeijer AJ, et al. Radiation-induced sarcoma: a challenge for the surgeon. Ann Surg Oncol. 2005;12:237–45.
doi: 10.1245/ASO.2005.03.041
Ghareeb ER, Bhargava R, Vargo JA, Florea AV, Beriwal S. Primary and radiation-induced breast angiosarcoma: clinicopathologic predictors of outcomes and the impact of adjuvant radiation therapy. Am J Clin Oncol. 2016;39:463–7.
doi: 10.1097/COC.0000000000000077
Friedrich AU, Reisenbichler ES, Heller DR, et al. Characteristics and long-term risk of breast angiosarcoma. Ann Surg Oncol. 2021. https://doi.org/10.1245/s10434-021-09689-2 .
Li GZ, Fairweather M, Wang J, Orgill DP, Bertagnolli MM, Raut CP. Cutaneous radiation-associated breast angiosarcoma: radicality of surgery impacts survival. Ann Surg. 2017;265:814–20.
doi: 10.1097/SLA.0000000000001753
Keung EZ, Chiang YJ, Cormier JN, et al. Treatment at low-volume hospitals is associated with reduced short-term and long-term outcomes for patients with retroperitoneal sarcoma. Cancer. 2018;124:4495–503.
doi: 10.1002/cncr.31699
Blay JY, Bonvalot S, Gouin F, Le Cesne A, Penel N. Criteria for reference centers for sarcomas: volume but also long-term multidisciplinary organisation. Ann Oncol. 2019;30:2008–9.
doi: 10.1093/annonc/mdz408
Blay JY, Honore C, Stoeckle E, et al. Surgery in reference centers improves survival of sarcoma patients: a nationwide study. Ann Oncol. 2019;30:1407.
doi: 10.1093/annonc/mdz170
Salminen SH, Sampo MM, Bohling TO, Tuomikoski L, Tarkkanen M, Blomqvist CP. Radiation-associated sarcoma after breast cancer in a nationwide population: increasing risk of angiosarcoma. Cancer Med. 2018;7:4825–35.
doi: 10.1002/cam4.1698
Perez-Ruiz E, Ribelles N, Sanchez-Munoz A, Roman A, Marquez A. Response to paclitaxel in a radiotherapy-induced breast angiosarcoma. Acta Oncol. 2009;48:1078–9.
doi: 10.1080/02841860902777115
Manner J, Radlwimmer B, Hohenberger P, et al. MYC high-level gene amplification is a distinctive feature of angiosarcomas after irradiation or chronic lymphedema. Am J Pathol. 2010;176:34–9.
doi: 10.2353/ajpath.2010.090637
Behjati S, Tarpey PS, Sheldon H, et al. Recurrent PTPRB and PLCG1 mutations in angiosarcoma. Nat Genet. 2014;46:376–9.
doi: 10.1038/ng.2921